Specific immunotherapy stimulates the binding of histamine H2 receptor antagonist by lymphocytes.
The binding of antagonists of histamine receptors H1 (promethazine) and H2 (ranitidine) by peripheral blood lymphocytes from pollinotics was determined before and after the course of immunotherapy. We found that lymphocytes from atopic subjects showed significant decrease in the binding of H2 receptor antagonist as compared to control subjects. Specific immunotherapy induced statistically significant increase in H2 receptor antagonist binding, which correlated with the improvement of clinical symptoms.
Zak-Nejmark
T
T
Department of Internal Diseases and Allergology, Medical Academy, Wrocław, Poland.
Małolepszy
J
J
Nadobna
G
G
Kuczyńska-Sekieta
K
K
Marczyńska-Sarul
E
E
Jutel
M
M
D000293:Adolescent; D000328:Adult; D003233:Conjunctivitis, Allergic / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D003888:Desensitization, Immunologic; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D011398:Promethazine / Q000378:metabolism* / Q000494:pharmacology; D011899:Ranitidine / Q000378:metabolism* / Q000494:pharmacology; D011970:Receptors, Histamine H2 / Q000187:drug effects* / Q000378:metabolism; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D011970:Receptors, Histamine H2; D011899:Ranitidine; D011398:Promethazine